z-logo
Premium
Anti‐inflammatory activity of lanoconazole, a topical antifungal agent
Author(s) -
Uratsuji Hideya,
Nakamura Aki,
Yamada Yoshihito,
Hashimoto Kei,
Matsumoto Tatsumi,
Ikeda Fumiaki,
Ishii Ritsuko
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12297
Subject(s) - peripheral blood mononuclear cell , in vivo , contact dermatitis , pharmacology , antifungal , inflammation , in vitro , chemistry , irritant contact dermatitis , interleukin , immunology , cytokine , medicine , dermatology , allergy , biochemistry , biology , microbiology and biotechnology
Summary Topical antifungal agents which have anti‐inflammatory effects have the potential to provide additional clinical benefits. Therefore, an anti‐inflammatory activity of lanoconazole ( LCZ ), a topical antifungal agent, was investigated against in vitro and in vivo models of inflammation. The release of interleukin‐8 ( IL ‐8) from human epidermal keratinocytes stimulated by the addition of 100 μg ml −1 β‐glucan of S accharomyces cerevisiae was significantly inhibited by LCZ at the concentration of 10 −5  mol l −1 . The release of interferon‐γ and IL ‐2 from human peripheral blood mononuclear cells stimulated by the addition of 30 and 100 μg ml −1 phytohemagglutinin was significantly inhibited by LCZ at the concentrations of 10 −7 and 10 −6  mol l −1 , respectively. The increase in the ear thickness induced by topical application of 0.01% 12‐ O ‐tetradecanoyl phorbol‐13‐acetate and 1% 2,4,6‐trinitrochlorobenzene ( TNCB ) after sensitisation with 3% TNCB were established as the mouse models of irritant and contact dermatitis, respectively. Application of 1% and 3% LCZ showed a significant anti‐inflammatory activity against both the irritant and contact dermatitis models. These findings suggest that LCZ possesses an anti‐inflammatory activity, which may be partially helpful in the treatment of dermatomycoses.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here